Navigation Links
Medicago begins human clinical testing with its avian flu pandemic vaccine
Date:10/1/2009

QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has initiated a Phase I human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment is ongoing and vaccination has commenced. The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, tolerability and the immune response of the Company's H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of this study are expected during the fourth quarter of 2009.

"This first human study with our lead vaccine candidate confirms Medicago's development as a clinical stage company," said Louis P. Vezina, Chief Scientific Officer of Medicago. "This is an important step for our H5N1 vaccine candidate, which has the potential to be highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines."

About Medicago's pandemic flu vaccine candidate

Medicago's H5N1 vaccine candidate was formulated to protect against the avian influenza virus. It is manufactured in Nicotiana benthamiana, a relative of the tobacco plant, using the Company's proprietary VLP technology. VLPs have several advantages over traditional influenza vaccines. They resemble the virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material making them non-infectious and unable to replicate. Medicago's VLP-based vaccine has shown in preclinical studies it can provide cross- protection against different strains of avian flu, such as the Vietnam and Turkey strains. As Medicago's technology requires the genetic sequence of a viral strain and not the live influenza virus, vaccines can be manufactured within 4 weeks of obtaining the genetic
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
2. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
3. Medicago succesfully expresses VLP antigen for A H1N1 strain
4. Medicago initiates work on Swine Flu strain
5. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
6. Finance Committee Begins Markup - Lab Fee Converted to Medicare Cut
7. America's Organic Home-Fueling Movement Begins in Los Angeles
8. FluMist(R) Begins Shipping for 2009-2010 Influenza Season
9. Mach One Corporation Begins Trading on the OTC Bulletin Board Under the Symbol MNCN
10. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
11. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is designed for ... content, to analysis of athletic performance. Producing high-resolution slow-motion video , the ... to process with the naked eye. , Slow motion sequences are commonly ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
Breaking Biology Technology:Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Frank ... SPRINGS, Fla., Aug. 14 Milestone Biosciences,LLC, a privately ... niche oncology products, today,announced the appointment of Eric P. ... President, CEO and Co-founder, Frank,Jacobucci, will become President and ...
... (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company,focused ... Lenz, CPA, as,its Chief Financial Officer. Mr. Lenz ... experience in addition to significant experience in,capital raising ... to have someone with Brian,s broad financial and,public ...
... Turnover Increased by 45.7%, Profit Attributable ... KONG, Aug. 14 /Xinhua-PRNewswire/ -- Fufeng Group Limited,("Fufeng" ... integrated,manufacturer of corn-based biochemical products in China, today ... 30 June 2008., During the period under ...
Cached Biology Technology:Milestone Biosciences, LLC Further Strengthens Executive Management Team 2Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer 2Fufeng Announces 2008 Interim Results With Strong Sign of Recovery 2Fufeng Announces 2008 Interim Results With Strong Sign of Recovery 3
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... 13, 2010) Before Alzheimer,s patients experience memory loss, the ... A new study in mouse models by researchers at ... -- the powerhouses of the cell -- are one of ... in the online Early Edition of PNAS, also found that ...
... Ind. -- The red, metal-laden sludge that escaped a containment ... with the help of carbon sequestration, says an Indiana University ... The bauxite residue now covers 40 square kilometers south ... eight Hungarians and injured at least 150. The residue also ...
... , SALT LAKE CITY, Oct. 13, 2010 - Microbubbles are ... during a demonstration project in eastern China, microbubble technology developed ... a wide range of environmental cleanup efforts around the world. ... organics and heavy metals from industrial sites, and removing harmful ...
Cached Biology News:Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis 2Can Hungary's red sludge be made less toxic with carbon? 2University of Utah microbubbles clean dirty soil in China 2University of Utah microbubbles clean dirty soil in China 3
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
... Geneious does sequence alignment, 3D structure ... and more; all in a single application. ... several NCBI databases, Uniprot, sort and filter ... how you want it, rapidly searching, filtering ...
... a comprehensive suite of advanced statistics ... to reliably extract biological signals from ... containing thousands of samples, Partek Genomics ... will analyze large data sets on ...
Biology Products: